Search Results - "Shanley, Mayra"
-
1
GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells
Published in Frontiers in immunology (26-02-2021)“…Natural killer (NK) cells are innate lymphocytes recognized for their important role against tumor cells. NK cells expressing chimeric antigen receptors (CARs)…”
Get full text
Journal Article -
2
Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHD
Published in Frontiers in immunology (04-05-2021)“…Acute graft-vs.-host (GVHD) disease remains a common complication of allogeneic stem cell transplantation with very poor outcomes once the disease becomes…”
Get full text
Journal Article -
3
Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopenia
Published in Frontiers in immunology (20-09-2022)“…The current global platelet supply is often insufficient to meet all the transfusion needs of patients, in particular for those with alloimmune…”
Get full text
Journal Article -
4
Activated B cells suppress T-cell function through metabolic competition
Published in Journal for immunotherapy of cancer (01-12-2022)“…B cells play a pivotal role in regulating the immune response. The induction of B cell-mediated immunosuppressive function requires B cell activating signals…”
Get full text
Journal Article -
5
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
Published in Nature medicine (01-03-2024)“…There is a pressing need for allogeneic chimeric antigen receptor (CAR)-immune cell therapies that are safe, effective and affordable. We conducted a phase 1/2…”
Get full text
Journal Article -
6
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape
Published in Nature medicine (01-10-2022)“…Trogocytosis is an active process that transfers surface material from targeted to effector cells. Using multiple in vivo tumor models and clinical data, we…”
Get full text
Journal Article -
7
Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma
Published in Cell (04-01-2024)“…Deciphering the cell-state transitions underlying immune adaptation across time is fundamental for advancing biology. Empirical in vivo genomic technologies…”
Get more information
Journal Article -
8
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30 + Malignancies
Published in Clinical cancer research (01-07-2021)“…Natural killer (NK)-cell recognition and function against NK-resistant cancers remain substantial barriers to the broad application of NK-cell immunotherapy…”
Get full text
Journal Article -
9
Targeting the [alpha]v integrin/TGF-[beta] axis improves natural killer cell function against glioblastoma stem cells
Published in The Journal of clinical investigation (15-07-2021)“…Glioblastoma multiforme (GBM), the most aggressive brain cancer, recurs because glioblastoma stem cells (GSCs) are resistant to all standard therapies. We…”
Get full text
Journal Article -
10
NK Cell Dysfunction in CLL Is Mediated through SHP-1 Signaling and Is Associated with Poor Prognosis
Published in Blood (02-11-2023)“…Chronic lymphocytic leukemia (CLL) is a heterogeneous disease, presenting with a highly variable clinical course, outcome and response to therapy. This…”
Get full text
Journal Article -
11
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial
Published in Clinical cancer research (15-07-2020)“…Cytomegalovirus (CMV) antigens occur in glioblastoma but not in normal brains, making them desirable immunologic targets. Highly functional autologous…”
Get full text
Journal Article -
12
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD
Published in Cancer cell (12-08-2024)“…Glioblastoma (GBM) is an aggressive brain cancer with limited therapeutic options. Natural killer (NK) cells are innate immune cells with strong anti-tumor…”
Get more information
Journal Article -
13
Generation and Screening of Various CD70 CAR NK Cells Identify the Most Effective Construct Against Hematologic Malignancies
Published in Blood (02-11-2023)“…The ability to re-direct the intrinsic power of the immune system against cancer has resulted in unprecedented outcomes in certain patients with otherwise…”
Get full text
Journal Article -
14
Targeting T-Cell Lymphoma Using CD70-Directed Cord Blood-Derived CAR-NK Cells
Published in Blood (02-11-2023)“…T-cell lymphomas (TCL) are a heterogenous group of non-Hodgkin lymphoma characterized by resistance to conventional therapies posing an urgent need for safe…”
Get full text
Journal Article -
15
DAP10 Co-Stimulation Imparts Memory-like Features to CD5 Targeting Cord Blood Derived CAR-NK Cells
Published in Blood (02-11-2023)“…Relapsed/refractory T-cell malignancies have a particularly poor prognosis and novel therapies are direly needed. CD5 is a great candidate for adoptive…”
Get full text
Journal Article -
16
Author Correction: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape
Published in Nature medicine (01-03-2024)Get full text
Journal Article -
17
Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy
Published in Cell reports (Cambridge) (20-07-2021)“…Adoptive cell therapy with virus-specific T cells has been used successfully to treat life-threatening viral infections, supporting application of this…”
Get full text
Journal Article -
18
Epigenetic Scarring Leads to Irreversible NK Cell Dysfunction in Myeloid Malignancies
Published in Blood (02-11-2023)“…Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) belong to the same spectrum of myeloid malignancies and have extremely poor outcomes in the…”
Get full text
Journal Article -
19
BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML
Published in Science translational medicine (11-09-2024)“…Myelodysplastic syndrome and acute myeloid leukemia (AML) belong to a continuous disease spectrum of myeloid malignancies with poor prognosis in the…”
Get more information
Journal Article -
20
A phase I/II clinical trial of autologous CMV-specific T cells in glioblastoma (GBM) patients to reveal a lack of immune effector function
Published in Journal of clinical oncology (20-05-2020)“…Abstract only 2515 Background: Cytomegalovirus (CMV) antigens are present in > 90% of GBMs but not in normal brain making it an attractive immunological…”
Get full text
Journal Article